Kureasia Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 2.00 Cr
as on 16-11-2024
- Company Age 9 Year, 11 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.91 Cr
as on 16-11-2024
- Revenue 86.74%
(FY 2023)
- Profit 470.31%
(FY 2023)
- Ebitda 78.37%
(FY 2023)
- Net Worth 907.31%
(FY 2023)
- Total Assets 161.38%
(FY 2023)
About Kureasia Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹7.91 Cr.
Shaheer Ariz and Yashpal Arora serve as directors at the Company.
- CIN/LLPIN
U85100DL2015PTC288996
- Company No.
288996
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kureasia Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shaheer Ariz  | Director | 29-Dec-2015 | Current |
| Yashpal Arora | Director | 29-Dec-2015 | Current |
Financial Performance of Kureasia Pharma.
Kureasia Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 86.74% increase. The company also saw a substantial improvement in profitability, with a 470.31% increase in profit. The company's net worth Soared by an impressive increase of 907.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kureasia Pharma?
Unlock access to Kureasia Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Indisurg (India) Surgicals LlpActive 4 years 6 monthsShaheer Ariz and Yashpal Arora are mutual person
- Rockmed Pharma Private LimitedActive 11 years 7 months
Shaheer Ariz and Yashpal Arora are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Apr 2023 | ₹7.91 Cr | Open |
How Many Employees Work at Kureasia Pharma?
Unlock and access historical data on people associated with Kureasia Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kureasia Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kureasia Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
